Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 May 21;155(8):3054–3064. doi: 10.1210/en.2013-2116

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2014 by the Endocrine Society

This article has been published under the terms of the Creative Commons Attribution License (CC-BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Copyright for this article is retained by the author(s). Author(s) grant(s) The Endocrine Society the exclusive right to publish the article and identify itself as the original publisher.

PMC Copyright notice

Figure 3. — Effect of daily treatment of BMP and SMAD2/3 pathway inhibitor A83–01 on terminal differentiation of chorionic girdle trophoblast cells from day 30 and day 31 conceptuses. Pure populations of chorionic girdle cells were treated daily for 3 days in the presence or absence of 100 ng/mL BMP4, 1 μM A83–01 inhibitor, or both. The total number of binucleated cells was quantified in 5 randomly selected fields for each treatment group; the depicted pooled data represent the mean (of means) + SEM for 3 individual conceptuses at either gestational day 30 or day 31. Data were analyzed by repeated measures by 2 factors followed by Tukey multiple-comparison test (*, P ≤ .05; **, P ≤ .01; ****, P ≤ .0001 relative to corresponding vehicle cells. ^, P ≤ .05; ^^^, P ≤ .001; ^^^^, P ≤ .0001 relative to corresponding 100 ng/mL BMP4-treated cells. ###, P ≤ .001 relative to corresponding 100 ng/mL BMP4 plus 1 μM inhibitor-treated cells.